Lineage-specific biomarkers predict response to FGFR inhibition.

about

Lineage-specific biomarkers predict response to FGFR inhibition.

Item

http://www.wikidata.org/entity/Q39228091

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Lineage-specific biomarkers predict response to FGFR inhibition.

@en

Lineage-specific biomarkers predict response to FGFR inhibition.

@nl

type

Item

label

Lineage-specific biomarkers predict response to FGFR inhibition.

@en

Lineage-specific biomarkers predict response to FGFR inhibition.

@nl

prefLabel

Lineage-specific biomarkers predict response to FGFR inhibition.

@en

Lineage-specific biomarkers predict response to FGFR inhibition.

@nl

P1476

Lineage-specific biomarkers predict response to FGFR inhibition.

@en

P2093

David C Loch

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Exploiting genetic complexity in cancer to improve therapeutic strategies

Targeting mutant fibroblast growth factor receptors in cancer.

Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.

Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.

P304

1081-1083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-12-0486

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pamela M. Pollock

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23230185

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4300517

http://www.w3.org/2001/XMLSchema#string